Inhibrx Biosciences, Inc. (INBX) vs Ultragenyx Pharmaceutical Inc. (RARE)
Inhibrx Biosciences, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). Inhibrx Biosciences, Inc. has the higher net margin (0.00% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Inhibrx Biosciences, Inc. leads on 9 and Ultragenyx Pharmaceutical Inc. on 5.
Valuation
Profitability
| Metric | INBX | RARE | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 83.12% | 65.16% |
| Operating margin | 0.00% | (73.64%) | 0.00% |
| Net margin | 0.00% | (81.73%) | 0.00% |
| Free cash flow margin | 0.00% | (68.90%) | 0.00% |
| Return on equity | (1,773.60%) | 838.86% | (57.72%) |
| Return on assets | (75.44%) | (45.60%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack